Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer

Objectives: Gonadotropin-releasing hormone agonists are widely used as androgen deprivation therapy in many men with locally advanced or metastatic prostate cancer. Gonadotropin-releasing hormone agonists are delivered by intramuscular injection every 1, 3 or 6 months, but in some patients subcutaneous injection may be more appropriate. This study assessed the efficacy and safety profile of the gonadotropin-releasing hormone agonist, triptorelin pamoate, when administered by the subcutaneous route. Methods: In this multicentre, open-label, single-arm study, androgen deprivation therapy-naïve men with locally advanced or metastatic prostate cancer received the gonadotropin-releasing hormone agonist triptorelin pamoate 11.25 mg (3-month formulation) by the subcutaneous route twice (at baseline and 13 weeks later). The co-primary efficacy endpoints were the proportion of patients with a castration level of serum testosterone (<50 ng/dl) after 4 weeks, and of these, those still castrated after 26 weeks. Results: Of the 126 treated patients, 123 [97.6%; 95% confidence interval (CI): 93.2–99.5)] were castrated 4 weeks after the first subcutaneous injection, and 115/119 patients (96.6%; 95% CI: 91.6–99.1) castrated at 4 weeks maintained castration at 26 weeks. Median prostate-specific antigen levels were reduced by 64.2 and 96.0% at 4 and 26 weeks, respectively. The probability of maintaining a testosterone level <20 ng/dl up to 26 weeks was 90.0% (95% CI: 85.0–95.0). The most frequently occurring treatment-related adverse events were typical of gonadotropin-releasing hormone agonist treatment (hot flushes, increased weight, erectile dysfunction and hyperhidrosis). Conclusions: This study demonstrates that triptorelin pamoate 11.25 mg administered by the subcutaneous route every 3 months is as efficacious and well tolerated as administration via the intramuscular route in men with locally advanced or metastatic prostate cancer

La tuberculose humaine, anthropozoonose néolithique ou infection d’homininés du Pléistocène inférieur ?

International audienc

La tuberculose humaine, anthropozoonose néolithique ou infection d’homininés du Pléistocène inférieur ?

International audienc

New evidence for an early presence of human tuberculosis in the Fertile Crescent more than 10 milleniums ago, predating domestication period

International audienc

Au moins 10 000 ans ! Preuves pluridisciplinaires de l’ancienneté de la tuberculose humaine au Levant

International audienc

La tuberculose humaine, anthropozoonose néolithique ou infection d’homininés du Pléistocène inférieur ?

International audienc

Au moins 10 000 ans ! Preuves pluridisciplinaires de l’ancienneté de la tuberculose humaine au Levant

International audienc

New evidence for an early presence of human tuberculosis in the Fertile Crescent more than 10 milleniums ago, predating domestication period

International audienc